Xi'an Xintong Pharmaceutical Research Co.,ltd.
Clinical trials sponsored by Xi'an Xintong Pharmaceutical Research Co.,ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill XTYW007 enters human testing for fatty liver Results expected Feb 2027 (estimated)
- New hope for advanced liver cancer: experimental drug takes on standard therapy Results expected Feb 2027 (estimated)
- New hepatitis b drug shows promise in large trial Results expected Jun 2027 (estimated)
-
New hope for advanced liver cancer: experimental drug takes on standard therapy
Disease control OngoingThis study compares a new drug, pracytarabine, to the standard drug regorafenib in 60 people with advanced liver cancer that has stopped responding to targeted therapy and immunotherapy. The goal is to see if pracytarabine can help patients live longer. Participants receive eithe…
Phase 2/3 • Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hepatitis b drug shows promise in large trial
Disease control OngoingThis study tests a new medication called hepenofovir fumarate (HTS) for people with chronic hepatitis B, a long-term liver infection. About 1,444 adults aged 18-65 who have not been treated before (or stopped treatment at least 6 months ago) will take one of three doses of HTS or…
Phase 2/3 • Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC